The short version of peptide agonist fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-03-16. Anything still debated is marked as such rather than presented as settled.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 4,700 Da | Peptide of roughly forty amino acids |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist class |
| Research code | LY3437943 | Internal development designation |
| Compound class | Incretin mimetic peptide | Synthetic, not a biologic extract |
| Development status | Investigational | No general regulatory approval |
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
=== Open microchannels === The behavior of fluids and their control in open microchannels came into focus around 2005 and applied in air-to-liquid sample collection and chromatography. In open microfluidics, at least one boundary of the system is removed, exposing the fluid to air or another interface (i.e. liquid). Advantages of open microfluidics include accessibility to the flowing liquid for intervention, larger liquid-gas surface area, and minimized bubble formation. Another advantage of open microfluidics is the ability to integrate open systems with surface-tension driven fluid flow, which eliminates the need for external pumping methods such as peristaltic or syringe pumps. Open microfluidic devices are also easy and inexpensive to fabricate by milling, thermoforming, and hot embossing. In addition, open microfluidics eliminates the need to glue or bond a cover for devices, which could be detrimental to capillary flows. Examples of open microfluidics include open-channel microfluidics, rail-based microfluidics, paper-based, and thread-based microfluidics. Disadvantages to open systems include susceptibility to evaporation, contamination, and limited flow rate.
In September 1984, during a briefing session chaired by He Zai, the secretary-general of the CCP Central Organization Department, Xi's strategic vision and comprehensive understanding of Zhengding County's development were highlighted. He Zai, along with Wei Jianxing, deputy head of the CCP Central Organization Department, communicated these findings to Hu Yaobang, describing Xi as a leader with a strategic outlook and a strong alliance ideology between workers and peasants. In 1985, Xi participated in a study tour on corn processing and traveled to Iowa, the United States, to study agricultural production and corn processing technology. During his visit to the U.S., the CCP Central Organization Department decided to transfer him to Xiamen as a member of the Standing Committee of the CCP Xiamen Municipal Committee and as vice mayor.
=== Hearing loss === Undiagnosed hearing loss in a child can have serious effects on many developmental areas, including language, social interactions, emotions, cognitive ability, academic performance and vocational skills, any combination of which can have negative impacts on the quality of life. The serious impacts of a late diagnosis, combined with the high incidence (estimated at 1 - 3 per 1000 live births, and as high as 4% for neonatal intensive care unit patients) have been the driving forces behind screening programs designed to identify infants with hearing loss as early as possible. Early identification allows these patients and their families to access the necessary resources to help them maximize their developmental outcomes.
Tetra Brik is a brand name for a carton package produced by the Swedish packaging company Tetra Pak. Its shape is cubic or cuboid, and it is available with or without various different caps. The Tetra Brik is the best-known and most sold package in the Tetra Pak packaging family, to the extent that Tetra Brik is sometimes mistaken for the brand name. The Tetra Brik comes in either chilled (Tetra Brik) or ambient (Tetra Brik Aseptic) package types.
A symbiotic culture of bacteria and yeast (SCOBY) is a culinary symbiotic fermentation culture (starter) consisting of lactic acid bacteria (LAB), acetic acid bacteria (AAB), and yeast which arises in the preparation of sour foods and beverages such as kombucha. Beer and wine also undergo fermentation with yeast, but the LAB and AAB components unique to the SCOBY are usually viewed as a source of spoilage rather than a desired addition. Both LAB and AAB enter on the surface of barley and malt in beer fermentation and grapes in wine fermentation; LAB lowers the pH of the beer or wine while AAB takes the ethanol produced from the yeast and oxidizes it further into vinegar, resulting in a sour taste and smell. AAB are also responsible for the formation of the cellulose SCOBY. SCOBY most accurately refers to the culture of bacteria and yeast suspended in the fermentation media, but it also is commonly used to refer to the gelatinous biofilm or microbial mat found floating at the container's air–liquid interface. This bacterial cellulose mat is referred to as a pellicle, and consists of a dense cellulose matrix with embedded bacteria and yeast cultures. SCOBY pellicles, like other fermentation starters, can serve the purpose of continuing the fermentation process into a new vessel and reproducing the desired product. This is done by introducing some of the previous culture to new, unfermented media.
Sources: en.wikipedia.org
In a prebiotic context, they argued that seawater would likely still be buffered and ferrous iron could inhibit oxidation. Steam and hydrogen sulfide. In 1999, after Miller suffered a stroke, he donated the contents of his laboratory to Bada. In an old cardboard box, Bada discovered unanalyzed samples from modified experiments that Miller had conducted in the 1950s. In a "volcanic" apparatus, Miller had amended an aspirating nozzle to shoot a jet of steam into the reaction chamber. Using high-performance liquid chromatography and mass spectrometry, Bada's lab analyzed old samples from a set of experiments Miller conducted with this apparatus and found some higher yields and a more diverse suite of amino acids. Bada speculated that injecting the steam into the spark could have split water into H and OH radicals, leading to more hydroxylated amino acids during Strecker synthesis. In a separate set of experiments, Miller added hydrogen sulfide (H2S) to the reducing atmosphere, and Bada's analyses of the products suggested order-of-magnitude higher yields, including some amino acids with sulfur moieties. Free electrons and charged microdroplets. A 2021 work highlighted the importance of the high-energy free electrons present in the experiment. It is these electrons that produce ions and radicals, and represent an aspect of the experiment that needs to be better understood. A 2025 study used charges from sprays of water instead of lightning to produce electricity.
Type I present in liver, kidney, thyroid, and (to a lesser extent) pituitary; it accounts for 80% of the deiodination of T4. Type II present in CNS, pituitary, brown adipose tissue, and heart vessel, which is predominantly intracellular. In the pituitary, it mediates negative feedback on thyroid-stimulating hormone. Type III present in placenta, CNS, and hemangioma. This deiodinase converts T4 into reverse T3, which, unlike T3, is inactive. T4 is synthesised in the thyroid follicular cell as follows.
Although it remained legal in some countries until after World War II, health risks, addiction, and widespread recreational use led most western countries to declare heroin a controlled substance by the latter half of the 20th century. In the late 1960s and early 1970s, the CIA supported anti-Communist Chinese Nationalists settled near the Sino-Burmese border and Hmong tribesmen in Laos. This helped the development of the Golden Triangle opium production region, which supplied about one-third of heroin consumed in the US after the 1973 American withdrawal from Vietnam. In 1999, Burma, the heartland of the Golden Triangle, was the second-largest producer of heroin, after Afghanistan. The Soviet-Afghan war led to increased production in the Pakistani-Afghan border regions, as US-backed mujaheddin militants raised money for arms from selling opium, contributing heavily to the modern Golden Crescent creation. By 1980, 60 percent of the heroin sold in the US originated in Afghanistan. It increased international production of heroin at lower prices in the 1980s. The trade shifted away from Sicily in the late 1970s as various criminal organizations violently fought with each other over the trade. The fighting also led to a stepped-up government law enforcement presence in Sicily. Following the discovery at a Jordanian airport of a toner cartridge that had been modified into an improvised explosive device, the resultant increased level of airfreight scrutiny led to a major shortage (drought) of heroin from October 2010 until April 2011.
(1936), Recollections and Reflections, London: G. Bell & Sons, Ltd. Republished as digital edition, Cambridge: University Press, 2011 (Cambridge Library Collection series). Thomson, George Paget. (1964) J.J. Thomson: Discoverer of the Electron. Great Britain: Thomas Nelson & Sons, Ltd. Davis, Eward Arthur & Falconer, Isobel (1997), J.J. Thomson and the Discovery of the Electron. ISBN 978-0-7484-0696-8 Falconer, Isobel (1988) "J.J. Thomson's Work on Positive Rays, 1906–1914" Historical Studies in the Physical and Biological Sciences 18(2) 265–310 Falconer, Isobel (2001) "Corpuscles to Electrons" in J Buchwald and A Warwick (eds) Histories of the Electron, Cambridge, Mass: MIT Press, pp. 77–100. Navarro, Jaume (2005). "J. J. Thomson on the Nature of Matter: Corpuscles and the Continuum". Centaurus. 47 (4): 259–282. Bibcode:2005Cent...47..259N. doi:10.1111/j.1600-0498.2005.00028.x. Downard, Kevin M. (2009). "J. J. Thomson goes to America". Journal of the American Society for Mass Spectrometry. 20 (11): 1964–1973. Bibcode:2009JASMS..20.1964D. doi:10.1016/j.jasms.2009.07.008. PMID 19734055. S2CID 34371775.
Sources: en.wikipedia.org
Centers for Disease Control: Obesity Data and Statistics American Obesity Treatment Association: Obesity Education and Statistics Archived February 28, 2021, at the Wayback Machine Contributors to Obesity | Tableau Public Archived January 3, 2015, at the Wayback Machine (infographic for the United States)
== Applications == The coupling of MS with LC systems is attractive because liquid chromatography can separate delicate and complex natural mixtures whose chemical composition needs to be well established, such as biological fluids, environmental samples, and drugs. Further, LC–MS has applications in volatile explosive residue analysis. Nowadays, LC–MS has become one of the most widely used chemical analysis techniques because more than 85% of natural chemical compounds are polar and thermally labile, and GC-MS cannot process these samples. As an example, HPLC–MS is regarded as the leading analytical technique for proteomics and pharmaceutical laboratories. Other important applications of LC–MS include the analysis of food, pesticides, and plant phenols.
Many of the early X-ray and radioactivity researchers went down in history as "martyrs for science." In her article, The Miracle and the Martyrs, Sarah Zobel of the University of Vermont tells of a 1920 banquet held to honor many of the pioneers of X-rays. Chicken was served for dinner: "Shortly after the meal was served, it could be seen that some of the participants were unable to enjoy the meal. After years of working with X-rays, many of the participants had lost fingers or hands due to radiation exposure and were unable to cut the meat themselves". The first American to die from radiation exposure was Clarence Madison Dally (1845-1904), an assistant to Thomas Alva Edison (1847-1931). Edison began studying X-rays almost immediately after Röntgen's discovery and delegated the task to Dally. Over time, Dally underwent more than 100 skin operations due to radiation damage. Eventually, both of his arms had to be amputated. His death led Edison to abandon all further X-ray research in 1904. One of the pioneers was the Austrian Gustav Kaiser (1871-1954), who in 1896 succeeded in photographing a double toe with an exposure time of 1½-2 hours. Due to the limited knowledge at the time, he also suffered severe radiation damage to his hands, losing several fingers and his right metacarpal. His work was the basis for, among other things, the construction of lead rubber aprons. Heinrich Albers-Schönberg (1865-1921), the world's first professor of radiology, recommended gonadal protection for testicles and ovaries in 1903.
== Ecology == In nature, A. roeperi is found primarily on the walls of ambrosia beetle galleries within a wide variety of host trees, where it survives by degrading compounds within wood. Traditionally, although they facilitate beetle growth and reproduction in nutritionally poor xylem tissue, ambrosia fungi are considered to be ineffective agents of wood decomposition, producing enzymes primarily dedicated to degradation of xylan, glucomannan, and callose (common components of hemicellulose) rather than cellulose, mirroring similar analyses made for various saprotrophic fungi. However, no equivalent studies have been performed on A. roeperi specifically, and it is worth noting that the article often cited in support of this conclusion only examined the fungal galleries of one beetle (Xyleborinus saxenii) associated with a different symbiont, Raffaelea sulfurea. Interestingly, metabolomic studies incorporating A. roeperi indicate that when growing on wood, this fungus possesses a lipid profile more similar to non-mutualistic Ceratocystidaceae than to other ambrosia fungi, further supporting the idea that making sweeping conclusions about fungal lifestyles based on data from apparently similar convergent systems can be misleading, as well as reinforcing how much remains to be learned about this and other ambrosial species. There are various molecular indications that hint at other ways in which A. roeperi may interact with its woody hosts.
== Structure and functions == Cryo-electron microscopy (Cryo-EM) study has revealed the structural architecture of PLOD3 within the lysyl O-linked glycosylation complex (KOGG complex), which plays a crucial role in procollagen maturation. The KOGG complex consists of a PLOD3 (LH3) dimer, a Procollagen galactosyltransferase 1 (ColGalT1) dimer, and UDP-bound cofactors, orchestrating the hydroxylation (by PLOD3) and dual glycosylation (galactosylation by ColGalT1 and glucosylation by PLOD3) of lysine residues in the endoplasmic reticulum (ER) lumen. These modifications are essential for collagen cross-linking, fibrillogenesis, and overall structural integrity. Additionally, the structural study suggests that the KOGG complex can polymerize into a larger, fiber-like enzyme supercomplex, which may further regulate collagen modification and assembly. Defects in PLOD3 function or glycosylation efficiency have been implicated in connective tissue disorders, including osteogenesis imperfecta and fibrosis-related diseases.
Sources: en.wikipedia.org
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.
No regulatory agency has approved it for routine medical use. It remains an investigational compound studied in controlled trials. Access outside research settings is not established.
Each receptor influences energy balance through different pathways. Combining them is intended to add fat loss from lowered intake and higher expenditure. The optimal balance among the three effects is still under study.
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.